China Resources Jiangzhong Pharmaceutical Co.,Ltd (SHA:600750)
26.35
+0.30 (1.15%)
Apr 8, 2026, 3:00 PM CST
SHA:600750 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 4,207 | 4,404 | 4,527 | 3,846 | 2,856 |
Other Revenue | 12.84 | 31.51 | 26.23 | 39.58 | 17.88 |
| 4,220 | 4,435 | 4,553 | 3,885 | 2,874 | |
Revenue Growth (YoY) | -4.87% | -2.59% | 17.19% | 35.19% | 17.72% |
Cost of Revenue | 1,458 | 1,634 | 1,648 | 1,384 | 1,026 |
Gross Profit | 2,762 | 2,801 | 2,906 | 2,501 | 1,848 |
Selling, General & Admin | 1,526 | 1,724 | 1,862 | 1,713 | 1,196 |
Research & Development | 152.79 | 130.43 | 141.42 | 99.97 | 87.82 |
Other Operating Expenses | 47.36 | 41.58 | 55.35 | 59.31 | 52.48 |
Operating Expenses | 1,724 | 1,904 | 2,058 | 1,874 | 1,336 |
Operating Income | 1,037 | 897.39 | 847.35 | 626.7 | 511.29 |
Interest Expense | -1.81 | -1.71 | -6.98 | -4.38 | -3.46 |
Interest & Investment Income | 75.73 | 77.48 | 68.79 | 37 | 26.3 |
Other Non Operating Income (Expenses) | 0.5 | 17.57 | -2.29 | -12.33 | -8.77 |
EBT Excluding Unusual Items | 1,112 | 990.74 | 906.87 | 646.99 | 525.36 |
Gain (Loss) on Sale of Investments | 0.59 | -11.46 | -40.05 | 57.1 | 51.25 |
Gain (Loss) on Sale of Assets | 0.61 | 1.84 | 1.22 | -0.13 | 0.9 |
Asset Writedown | -0.68 | -1.05 | -2.04 | - | - |
Other Unusual Items | 100.52 | 45.54 | 50.12 | 49.32 | 45.63 |
Pretax Income | 1,213 | 1,026 | 916.12 | 753.28 | 623.14 |
Income Tax Expense | 225.17 | 165.11 | 129.11 | 106.89 | 92.19 |
Earnings From Continuing Operations | 987.55 | 860.51 | 787.01 | 646.39 | 530.95 |
Net Income to Company | 987.55 | 860.51 | 787.01 | 646.39 | 530.95 |
Minority Interest in Earnings | -80.87 | -72.31 | -68.34 | -48.15 | -25.26 |
Net Income | 906.69 | 788.19 | 718.67 | 598.24 | 505.69 |
Net Income to Common | 906.69 | 788.19 | 718.67 | 598.24 | 505.69 |
Net Income Growth | 15.03% | 9.67% | 20.13% | 18.30% | 6.74% |
Shares Outstanding (Basic) | 634 | 631 | 719 | 630 | 632 |
Shares Outstanding (Diluted) | 634 | 631 | 719 | 630 | 632 |
Shares Change (YoY) | 0.55% | -12.26% | 14.12% | -0.38% | 0.07% |
EPS (Basic) | 1.43 | 1.25 | 1.00 | 0.95 | 0.80 |
EPS (Diluted) | 1.43 | 1.25 | 1.00 | 0.95 | 0.80 |
EPS Growth | 14.40% | 25.00% | 5.26% | 18.75% | 6.67% |
Free Cash Flow | 690.29 | 495.49 | 828.31 | 676.02 | 728.55 |
Free Cash Flow Per Share | 1.09 | 0.79 | 1.15 | 1.07 | 1.15 |
Dividend Per Share | 1.380 | 1.200 | 1.300 | 1.150 | 0.650 |
Dividend Growth | 15.00% | -7.69% | 13.04% | 76.92% | 140.74% |
Gross Margin | 65.45% | 63.16% | 63.81% | 64.37% | 64.29% |
Operating Margin | 24.58% | 20.23% | 18.61% | 16.13% | 17.79% |
Profit Margin | 21.49% | 17.77% | 15.78% | 15.40% | 17.59% |
Free Cash Flow Margin | 16.36% | 11.17% | 18.19% | 17.40% | 25.35% |
EBITDA | 1,184 | 1,033 | 971.28 | 746.78 | 626.2 |
EBITDA Margin | 28.06% | 23.28% | 21.33% | 19.22% | 21.79% |
D&A For EBITDA | 146.62 | 135.29 | 123.94 | 120.08 | 114.91 |
EBIT | 1,037 | 897.39 | 847.35 | 626.7 | 511.29 |
EBIT Margin | 24.58% | 20.23% | 18.61% | 16.13% | 17.79% |
Effective Tax Rate | 18.57% | 16.10% | 14.09% | 14.19% | 14.79% |
Revenue as Reported | 4,220 | 4,435 | 4,553 | 3,885 | 2,874 |
Advertising Expenses | 385.39 | 364.67 | 404.92 | 318.77 | 321.22 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.